top
Search terms
Results 1 - 10 of 18 - ordered by :
Pages: 1 2
Ejhf

Aims The use of an erythropoesis-stimulating agent, darbepoetin alfa (DA), to treat anaemia in patients with diabetes mellitus and chronic kidney disease was associated with a heightened risk of ...

European Journal of Heart Failure, Bello, Natalie A., Lewis, Eldrin F., Desai, Akshay S., Anand, Inder S., Krum, Henry, McMurray, John J.V., Olson, Kurt, Solomon, Scott D., Swedberg, Karl, van ...

Date : 01/11/2015 Item size : 53963 bytes
Ejhf

Introduction The growing elderly population coupled with a decline in mortality from myocardial infarction (MI) has seen the number of patients with heart failure (HF) secondary to coronary artery ...

European Journal of Heart Failure, Badar, Athar A., Perez‐Moreno, Ana C., Hawkins, Nathaniel M., Brunton, Alan P.T., Jhund, Pardeep S., Wong, Chih M., Solomon, Scott D., Granger, Christopher B., ...

Date : 01/02/2015 Item size : 168322 bytes
Ejhf

Patients The design and principal findings of CORONA have been reported in detail.11,12 Patients aged ≥60 years with chronic New York Heart Association (NYHA) class II-IV HF of ...

European Journal of Heart Failure, Inglis, Sally C., McMurray, John J.V., Böhm, Michael, Schaufelberger, Maria, Veldhuisen, Dirk J., Lindberg, Magnus, Dunselman, Peter, Hjalmarson, Åke, Kjekshus, ...

Date : 01/07/2010 Item size : 188376 bytes
Ejhf

Tel: +44 151 228 1616, Email: nathawkins@hotmail.com Search for more papers by this author Wang Duolao, Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, UKSearch for ...

European Journal of Heart Failure, Hawkins, Nathaniel M., Wang, Duolao, Petrie, Mark C., Pfeffer, Marc A., Swedberg, Karl, Granger, Christopher B., Yusuf, Salim, Solomon, Scott D., Östergren, Jan, ...

Date : 01/06/2010 Item size : 208846 bytes
Ejhf

Predictors of fatal and non‐fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A‐1, high‐sensitivity C‐reactive ...

European Journal of Heart Failure, Wedel, Hans, McMurray, John J.V., Lindberg, Magnus, Wikstrand, John, Cleland, John G.F., Cornel, Jan H., Dunselman, Peter, Hjalmarson, Åke, Kjekshus, John, ...

Date : 01/03/2009 Item size : 233317 bytes
Ehjournal

Methods and results We followed 8561 patients with T2DM and evidence of chronic kidney disease, CV disease, or both in ALTITUDE until the first non-fatal CV or renal event of myocardial infarction ...

European Heart Journal, Jhund, Pardeep S., McMurray, John J.V., Chaturvedi, Nish, Brunel, Patrick, Desai, Akshay S., Finn, Peter V., Haffner, Steven M., Solomon, Scott D., Weinrauch, Larry A., ...

Date : 21/09/2015
Ehjournal

Improvement in glycaemic control is no longer an acceptable surrogate for efficacy (or safety) with regard to cardiovascular outcomes.35 Safety must be formally demonstrated in adequately powered ...

European Heart Journal, Zannad, Faiez, Stough, Wendy Gattis, Pocock, Stuart J., Sleight, Peter, Cushman, William C, Cleland, John G.F., McMurray, John J.V., Lonn, Eva, Geller, Nancy L., Wedel, Hans, ...

Date : 01/05/2012 Item size : 369253 bytes
Ehjournal

See page 2246 for the editorial comment on this article (doi:10.1093/eurheartj/ehs129) Introduction Multiple randomized trials have shown that HMG-CoA reductase inhibitors (statins) reduce morbidity ...

European Heart Journal, Gullestad, Lars, Ueland, Thor, Kjekshus, John, Nymo, Ståle H., Hulthe, Johannes, Muntendam, Pieter, Adourian, Aram, Böhm, Michael, van Veldhuisen, Dirk J., Komajda, ...

Date : 01/09/2012
Ehjournal

The search combined terms related to diabetes (diabetes, insulin resistance, dysglycaemia, hyperglycaemia, glucose tolerance, with terms related to HF (heart failure, ventricular dysfunction, ...

European Heart Journal, MacDonald, Michael R., Petrie, Mark C., Hawkins, Nathaniel M., Petrie, John R., Fisher, Miles, McKelvie, Robert, Aguilar, David, Krum, Henry, McMurray, John J.V.

Date : 01/05/2008 Item size : 610220 bytes
Ehjournal

Improvement in glycaemic control is no longer an acceptable surrogate for efficacy (or safety) with regard to cardiovascular outcomes.35 Safety must be formally demonstrated in adequately powered ...

European Heart Journal, Zannad, Faiez, Stough, Wendy Gattis, Pocock, Stuart J., Sleight, Peter, Cushman, William C, Cleland, John G.F., McMurray, John J.V., Lonn, Eva, Geller, Nancy L., Wedel, Hans, ...

Date : 01/05/2012